{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:48:42Z","timestamp":1780336122378,"version":"3.54.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":244,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Monitoring drug safety is a central concern throughout the drug life cycle. Information about toxicity and adverse events is generated at every stage of this life cycle, and stakeholders have a strong interest in applying text mining and artificial intelligence (AI) methods to manage the ever-increasing volume of this information. Recognizing the importance of these applications and the role of challenge evaluations to drive progress in text mining, the organizers of BioCreative VII (Critical Assessment of Information Extraction in Biology) convened a panel of experts to explore \u2018Challenges in Mining Drug Adverse Reactions\u2019. This article is an outgrowth of the panel; each panelist has highlighted specific text mining application(s), based on their research and their experiences in organizing text mining challenge evaluations. While these highlighted applications only sample the complexity of this problem space, they reveal both opportunities and challenges for text mining to aid in the complex process of drug discovery, testing, marketing and post-market surveillance. Stakeholders are eager to embrace natural language processing and AI tools to help in this process, provided that these tools can be demonstrated to add value to stakeholder workflows. This creates an opportunity for the BioCreative community to work in partnership with regulatory agencies, pharma and the text mining community to identify next steps for future challenge evaluations.<\/jats:p>","DOI":"10.1093\/database\/baac071","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T02:07:53Z","timestamp":1662084473000},"source":"Crossref","is-referenced-by-count":19,"title":["Challenges and opportunities for mining adverse drug reactions: perspectives from pharma, regulatory agencies, healthcare providers and consumers"],"prefix":"10.1093","volume":"2022","author":[{"given":"Graciela","family":"Gonzalez-Hernandez","sequence":"first","affiliation":[{"name":"Department of Computational Biomedicine, Cedars-Sinai Medical Center , 700 N. San Vicente Blvd., West Hollywood, CA 90069, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krallinger","sequence":"additional","affiliation":[{"name":"Life Sciences\u2014Text Mining, Barcelona Supercomputing Center , Pla\u00e7a Eusebi G\u00fcell, 1-3, Barcelona 08034, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center of Drug Evaluation and Research, FDA , 10903 New Hampshire Ave, Silver Spring, MD 20993, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Rodriguez-Esteban","sequence":"additional","affiliation":[{"name":"Roche Innovation Center Basel, Roche Pharmaceuticals , Grenzacherstrasse 124, Basel 4070, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Uzuner","sequence":"additional","affiliation":[{"name":"Information Sciences and Technology, George Mason University , 4400 University Dr, Fairfax, VA 22030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-0720","authenticated-orcid":false,"given":"Lynette","family":"Hirschman","sequence":"additional","affiliation":[{"name":"MITRE Labs, The MITRE Corporation , 202 Burlington Rd., Bedford, MA 01730, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"2022090202074613800_R1","doi-asserted-by":"publisher","DOI":"10.1093\/database\/bau039","article-title":"BioCreative-IV virtual issue","volume":"2014","author":"Arighi","year":"2014","journal-title":"Database (Oxford)"},{"key":"2022090202074613800_R2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-S8-S1","article-title":"Overview of the BioCreative III Workshop","volume":"12","author":"Arighi","year":"2011","journal-title":"BMC Bioinform."},{"key":"2022090202074613800_R3","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-s2-s1","article-title":"Evaluation of text-mining systems for biology: overview of the Second BioCreative community challenge","volume":"9 Suppl 2","author":"Krallinger","year":"2008","journal-title":"Genome Biol."},{"key":"2022090202074613800_R4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-6-S1-S1","article-title":"Overview of BioCreAtIvE: critical assessment of information extraction for biology","volume":"6 Suppl 1","author":"Hirschman","year":"2005","journal-title":"BMC Bioinform."},{"key":"2022090202074613800_R5","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2946-7-S1-S1","article-title":"CHEMDNER: the drugs and chemical names extraction challenge","volume":"7","author":"Krallinger","year":"2015","journal-title":"J Cheminform"},{"key":"2022090202074613800_R6","doi-asserted-by":"publisher","first-page":"W484","DOI":"10.1093\/nar\/gkx462","article-title":"LimTox: a web tool for applied text mining of adverse event and toxicity associations of compounds, drugs and genes","volume":"45","author":"Canada","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"2022090202074613800_R7","article-title":"Virtual BioCreative Issue","author":"Database (Oxford)"},{"key":"2022090202074613800_R8","article-title":". Best Practices in Drug and Biological Product Postmarket Safety Surveillance for FDA Staff","year":"2019"},{"key":"2022090202074613800_R9","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/pds.3395","article-title":"Evaluation of FDA safety-related drug label changes in 2010","volume":"22","author":"Lester","year":"2013","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2022090202074613800_R10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40264-021-01142-3","article-title":"Sources of evidence triggering and supporting safety-related labeling changes: a 10-year longitudinal assessment of 22 new molecular entities approved in 2008 by the US Food and Drug Administration","volume":"45","author":"Croteau","year":"2022","journal-title":"Drug Saf."},{"key":"2022090202074613800_R11","article-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","author":"Efficacy Guidelines"},{"key":"2022090202074613800_R12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jbi.2017.07.012","article-title":"Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review","volume":"73","author":"Kreimeyer","year":"2017","journal-title":"J. Biomed. Inform."},{"key":"2022090202074613800_R13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3233\/978-1-61499-432-9-1178","article-title":"Novel algorithms for improved pattern recognition using the US FDA Adverse Event Network Analyzer","volume":"205","author":"Botsis","year":"2014","journal-title":"Stud. Health Technol. Inform."},{"key":"2022090202074613800_R14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40264-013-0064-4","article-title":"Application of information retrieval approaches to case classification in the vaccine adverse event reporting system","volume":"36","author":"Botsis","year":"2013","journal-title":"Drug Saf."},{"key":"2022090202074613800_R15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1145\/3019612.3022875","article-title":"Towards transforming FDA adverse event narratives into actionable structured data for improved pharmacovigilance","author":"Wunnava"},{"key":"2022090202074613800_R16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40290-021-00398-5","article-title":"Leveraging case narratives to enhance patient age ascertainment from adverse event reports","volume":"35","author":"Pham","year":"2021","journal-title":"Pharmaceut. Med."},{"key":"2022090202074613800_R17","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104517","article-title":"Feature engineering and machine learning for causality assessment in pharmacovigilance: lessons learned from application to the FDA Adverse Event Reporting System","volume":"135","author":"Kreimeyer","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"2022090202074613800_R18","article-title":"Overview of the TAC 2017 adverse reaction extraction from drug labels track","author":"Roberts","year":"2017"},{"key":"2022090202074613800_R19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jbi.2018.05.019","article-title":"Evaluation of natural language processing (NLP) systems to annotate drug product labeling with MedDRA terminology","volume":"83","author":"Ly","year":"2018","journal-title":"J. Biomed. Inform."},{"key":"2022090202074613800_R20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40264-020-00996-3","article-title":"ADE eval: an evaluation of text processing systems for adverse event extraction from drug labels for pharmacovigilance","volume":"44","author":"Bayer","year":"2021","journal-title":"Drug Saf."},{"key":"2022090202074613800_R21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jamia\/ocaa028","article-title":"Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration\u2019s Sentinel system","volume":"27","author":"Brown","year":"2020","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"2022090202074613800_R22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/15353702211052280","article-title":"Emerging technologies and their impact on regulatory science","volume":"247","author":"Anklam","year":"2022","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"2022090202074613800_R23","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/pds.4645","article-title":"Evaluating automated approaches to anaphylaxis case classification using unstructured data from the FDA Sentinel System","volume":"27","author":"Ball","year":"2018","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2022090202074613800_R24","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-021-00542-0","article-title":"Broadening the reach of the FDA Sentinel system: a roadmap for integrating electronic health record data in a causal analysis framework","volume":"4","author":"Desai","year":"2021","journal-title":"NPJ Digit. Med."},{"key":"2022090202074613800_R25","article-title":"Good practice guide on recording, coding, reporting and assessment of medication errors","author":"Pharmacovigilance Risk Assessment Committee (PRAC)","year":"2015"},{"key":"2022090202074613800_R26","article-title":"U.S. Food and Drug Administration. Drug Safety Priorities 2016: Initiatives and Innovation","author":"Center for Drug Evaluation and Research","year":"2016"},{"key":"2022090202074613800_R27","article-title":"Guidelines on good pharmacovigilance practices (GVP). Module VI \u2013 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev. 2) [online]","author":"European Medicines Agency","year":"2022"},{"key":"2022090202074613800_R28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cpt.1833","article-title":"Different strategies to execute multi-database studies for medicines surveillance in real-world setting: a reflection on the European model","volume":"108","author":"Gini","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"2022090202074613800_R29","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/pds.3739","article-title":"Longitudinal medical records as a complement to routine drug safety signal analysis","volume":"24","author":"Star","year":"2015","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2022090202074613800_R30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40264-020-01030-2","article-title":"Validating intelligent automation systems in pharmacovigilance: insights from good manufacturing practices","volume":"44","author":"Huysentruyt","year":"2021","journal-title":"Drug Saf."},{"key":"2022090202074613800_R31","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bcp.15024","article-title":"Numbers of spontaneous reports: how to use and interpret?","volume":"88","author":"Kant","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2022090202074613800_R32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s43441-019-00023-3","article-title":"Utilizing advanced technologies to augment pharmacovigilance systems: challenges and opportunities","volume":"54","author":"Lewis","year":"2020","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2022090202074613800_R33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40290-018-0251-9","article-title":"Training augmented intelligent capabilities for pharmacovigilance: applying deep-learning approaches to individual case safety report processing","volume":"32","author":"Abatemarco","year":"2018","journal-title":"Pharmaceut. Med."},{"key":"2022090202074613800_R34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40290-019-00269-0","article-title":"Artificial intelligence within pharmacovigilance: a means to identify cognitive services and the framework for their validation","volume":"33","author":"Mockute","year":"2019","journal-title":"Pharmaceut. Med."},{"key":"2022090202074613800_R35","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa363","article-title":"Automation in signal management in pharmacovigilance-an insight","volume":"22","author":"Wadhwa","year":"2021","journal-title":"Brief. Bioinformatics"},{"key":"2022090202074613800_R36","doi-asserted-by":"publisher","DOI":"10.1186\/2041-1480-3-15","article-title":"Extraction of potential adverse drug events from medical case reports","volume":"3","author":"Gurulingappa","year":"2012","journal-title":"J. Biomed. Semantics"},{"key":"2022090202074613800_R37","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-14-13","article-title":"A pipeline to extract drug-adverse event pairs from multiple data sources","volume":"14","author":"Yeleswarapu","year":"2014","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"2022090202074613800_R38","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2019.100190","article-title":"A novel method for drug-adverse event extraction using machine learning","volume":"17","author":"Negi","year":"2019","journal-title":"Inform. Med. Unlocked"},{"key":"2022090202074613800_R39","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-020-1097-0","article-title":"Implementation and comparison of two text mining methods with a standard pharmacovigilance method for signal detection of medication errors","volume":"20","author":"Eskildsen","year":"2020","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"2022090202074613800_R40","article-title":"Overview of DrugProt BioCreative VII track: quality evaluation and large scale text mining of drug-gene\/protein relations Proceedings of the BioCreative VII Challenge Evaluation Workshop, 11","author":"Miranda-Escalada","year":"2021"},{"key":"2022090202074613800_R41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00415","article-title":"Computational advances in drug safety: systematic and mapping review of knowledge engineering based approaches","volume":"10","author":"Natsiavas","year":"2019","journal-title":"Front. Pharmacol."},{"key":"2022090202074613800_R42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-1-4939-9089-4_13","article-title":"Text mining for drug discovery","volume":"1939","author":"Zheng","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"2022090202074613800_R43","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab750","article-title":"AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development","volume":"38","author":"Jornod","year":"2021","journal-title":"Bioinformatics"},{"key":"2022090202074613800_R44","doi-asserted-by":"crossref","article-title":"Leveraging UMLS-driven NLP to Enhance Identification Of Influenza Predictors Derived from Electronic Medical Record Data","author":"Stephens","DOI":"10.1101\/2020.04.24.058982"},{"key":"2022090202074613800_R45","first-page":"1","article-title":"Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008","volume-title":"NCHS Data Brief","author":"Gu","year":"2010"},{"key":"2022090202074613800_R46","article-title":"Preventable Adverse Drug Reactions: A Focus on Drug Interactions"},{"key":"2022090202074613800_R47","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jbi.2009.08.007","article-title":"What can natural language processing do for clinical decision support?","volume":"42","author":"Demner-Fushman","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"2022090202074613800_R48","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jbi.2015.10.007","article-title":"Practical applications for natural language processing in clinical research: the 2014 i2b2\/UTHealth shared tasks","volume":"58","author":"Uzuner","year":"2015","journal-title":"J. Biomed. Inform."},{"key":"2022090202074613800_R49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/clpt.2010.260","article-title":"The emerging role of electronic medical records in pharmacogenomics","volume":"89","author":"Wilke","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"2022090202074613800_R50","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jaip.2018.11.023","article-title":"Drug hypersensitivity reactions documented in electronic health records within a large health system","volume":"7","author":"Wong","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2022090202074613800_R51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/jamia\/ocz166","article-title":"2018 n2c2 shared task on adverse drug events and medication extraction in electronic health records","volume":"27","author":"Henry","year":"2020","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"2022090202074613800_R52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40264-018-0762-z","article-title":"Overview of the first natural language processing challenge for extracting medication, indication, and adverse drug events from electronic health record notes (MADE 1.0)","volume":"42","author":"Jagannatha","year":"2019","journal-title":"Drug Saf."},{"key":"2022090202074613800_R53","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocy114","article-title":"Data and systems for medication-related text classification and concept normalization from Twitter: insights from the Social Media Mining for Health (SMM4H)-2017 shared task","volume-title":"J Am Med Inform Assoc","year":"2018"},{"key":"2022090202074613800_R54","article-title":"Overview of the second social media mining for health (SMM4H) shared tasks at AMIA 2017","volume-title":"Training 1(10,822): 1239","author":"Sarker"},{"key":"2022090202074613800_R55","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.35","article-title":"MIMIC-III, a freely accessible critical care database","volume":"3","author":"Johnson","year":"2016","journal-title":"Sci. Data"},{"key":"2022090202074613800_R56","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","article-title":"Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles?","volume":"37","author":"Michel","year":"2017","journal-title":"Clin. Drug Investig"},{"key":"2022090202074613800_R57","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdaq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann. Oncol."},{"key":"2022090202074613800_R58","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"2022090202074613800_R59","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00002018-200730080-00003","article-title":"Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance","volume":"30","author":"Golomb","year":"2007","journal-title":"Drug Saf."},{"key":"2022090202074613800_R60","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/jcp.0b013e31815152a5","article-title":"Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence","volume":"27","author":"Goethe","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"2022090202074613800_R61","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.288.11.1403","article-title":"Discontinuation of use and switching of antidepressants: influence of patient-physician communication","volume":"288","author":"Bull","year":"2002","journal-title":"JAMA"},{"key":"2022090202074613800_R62","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00004850-200105000-00004","article-title":"Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline","volume":"16","author":"Fakhoury","year":"2001","journal-title":"Int. Clin. Psychopharmacol."},{"key":"2022090202074613800_R63","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3371\/CSRP.5.3.3","article-title":"Medication adherence and subjective weight perception in patients with first-episode psychotic disorder","volume":"5","author":"Wong","year":"2011","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"2022090202074613800_R64","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.mayocp.2012.04.017","article-title":"Ten common questions (and their answers) about off-label drug use","volume":"87","author":"Wittich","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"2022090202074613800_R65","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2022090202074613800_R66","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/0003-4819-157-11-201212040-00538","article-title":"Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review","volume":"157","author":"Viswanathan","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"2022090202074613800_R67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"2022090202074613800_R68","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bcp.12746","article-title":"Systematic review on the prevalence, frequency and comparative value of adverse events data in social media","volume":"80","author":"Golder","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2022090202074613800_R69","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8953","article-title":"Assessment of beliefs and attitudes about statins posted on Twitter: a qualitative study","volume":"3","author":"Golder","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"2022090202074613800_R70","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/jamia\/ocab114","article-title":"DeepADEMiner: a deep learning pharmacovigilance pipeline for extraction and normalization of adverse drug event mentions on Twitter","volume":"28","author":"Magge","year":"2021","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"2022090202074613800_R71","article-title":"Pharmacological substances, compounds and proteins named entity recognition track","author":"Gonzalez-Agirre","year":"2019"},{"key":"2022090202074613800_R72","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","article-title":"Good signal detection practices: evidence from IMI PROTECT","volume":"39","author":"Wisniewski","year":"2016","journal-title":"Drug Saf."}],"container-title":["Database"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baac071\/45650076\/baac071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/database\/article-pdf\/doi\/10.1093\/database\/baac071\/45650076\/baac071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T02:07:59Z","timestamp":1662084479000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/database\/article\/doi\/10.1093\/database\/baac071\/6682867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":72,"URL":"https:\/\/doi.org\/10.1093\/database\/baac071","relation":{},"ISSN":["1758-0463"],"issn-type":[{"value":"1758-0463","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"baac071"}}